NEW YORK, March 19, 2026 (GLOBE NEWSWIRE)-- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of ...
Hello, everyone, and welcome to Zepp Health Corporation's Fourth Quarter and Full Year 2025 Earnings Conference Call. The company ...
GPGI, Inc. (NYSE:GPGI) Q4 2025 Earnings Call Transcript March 12, 2026 GPGI, Inc. misses on earnings expectations. Reported EPS is $0.23 EPS, expectations were $0.2336. Operator: Good day, and thank ...
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript March 12, 2026 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.15451 EPS, expectations ...
Spyre Therapeutics, Inc. earns a Strong Buy on Phase 1 wins, IBD/RA pipeline catalysts, and $757M cash runway. Click for this ...
Gulf Business on MSN
Food on the move: How Careem, talabat and noon are keeping UAE orders moving
For millions of residents in the UAE, ordering food or groceries through a smartphone app remains a routine part of daily life ...
Gain the skills, dexterity and confidence to propel your career into senior management. Whether the goal is to create a standalone solution or fashion part of a complex talent development initiative, ...
Strong enrollment momentum in Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001); clinical update expected in 1H/2026 with an additional update in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results